biosimilars

News
FDA approves second Neupogen biosimilar

FDA approves second Neupogen biosimilar

Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.

Market Access
Biosimilar switches and healthcare gains

Biosimilar switches and healthcare gains

Despite being used across Europe for more than a decade, biosimilar medications are still something of a mystery among those outside the sector.